Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Wins $2M to Validate Prostate Disease Markers, Develop Dx for Asian Consortium

NEW YORK (GenomeWeb News) — GeneNews today said it will pocket $2 million as part of a deal to develop and validate biomarkers for prostate diseases, including cancer, for an unnamed Asian biomedical consortium.
 
GeneNews said it will use its Sentinel Principle and Discovery Funnel technologies to find the biomarkers. If a biomarker panel is successfully validated, GeneNews will develop and market a blood-based diagnostic called ProstateSentry.
 
Toronto-based GeneNews said that under the agreement it will hold all of the intellectual property stemming from the research, but that the consortium will receive “certain royalties” from sales of the product.
 
The company has a similar blood-based diagnostic for colon cancer, called ColonSentry, in more advanced stages of development.
 
"While our primary focus is currently on the development of … ColonSentry, this non-dilutive investment will allow us to accelerate the development of a second product in our Sentry pipeline,” GeneNews CEO K. Wayne Marshall said in a statement.
 
The company did not immediately return a call seeking more information about the consortium.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.